190 related articles for article (PubMed ID: 37349325)
1. Oncogenic structural aberration landscape in gastric cancer genomes.
Saito-Adachi M; Hama N; Totoki Y; Nakamura H; Arai Y; Hosoda F; Rokutan H; Yachida S; Kato M; Fukagawa A; Shibata T
Nat Commun; 2023 Jun; 14(1):3688. PubMed ID: 37349325
[TBL] [Abstract][Full Text] [Related]
2. Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent
Ooi WF; Nargund AM; Lim KJ; Zhang S; Xing M; Mandoli A; Lim JQ; Ho SWT; Guo Y; Yao X; Lin SJ; Nandi T; Xu C; Ong X; Lee M; Tan AL; Lam YN; Teo JX; Kaneda A; White KP; Lim WK; Rozen SG; Teh BT; Li S; Skanderup AJ; Tan P
Gut; 2020 Jun; 69(6):1039-1052. PubMed ID: 31542774
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
Smid M; Schmidt MK; Prager-van der Smissen WJC; Ruigrok-Ritstier K; Schreurs MAC; Cornelissen S; Garcia AM; Broeks A; Timmermans AM; Trapman-Jansen AMAC; Collée JM; Adank MA; Hooning MJ; Martens JWM; Hollestelle A
Breast Cancer Res; 2023 May; 25(1):53. PubMed ID: 37161532
[TBL] [Abstract][Full Text] [Related]
4. Fine-Scale Characterization of Genomic Structural Variation in the Human Genome Reveals Adaptive and Biomedically Relevant Hotspots.
Lin YL; Gokcumen O
Genome Biol Evol; 2019 Apr; 11(4):1136-1151. PubMed ID: 30887040
[TBL] [Abstract][Full Text] [Related]
5. Somatic structural variation signatures in pediatric brain tumors.
Yang Y; Yang L
Cell Rep; 2023 Oct; 42(10):113276. PubMed ID: 37851574
[TBL] [Abstract][Full Text] [Related]
6. Whole-genome sequencing reveals novel tandem-duplication hotspots and a prognostic mutational signature in gastric cancer.
Xing R; Zhou Y; Yu J; Yu Y; Nie Y; Luo W; Yang C; Xiong T; Wu WKK; Li Z; Bing Y; Lin S; Zhang Y; Hu Y; Li L; Han L; Yang C; Huang S; Huang S; Zhou R; Li J; Wu K; Fan D; Tang G; Dou J; Zhu Z; Ji J; Fang X; Lu Y
Nat Commun; 2019 May; 10(1):2037. PubMed ID: 31048690
[TBL] [Abstract][Full Text] [Related]
7. Revealing the impact of structural variants in multiple myeloma.
Rustad EH; Yellapantula VD; Glodzik D; Maclachlan KH; Diamond B; Boyle EM; Ashby C; Blaney P; Gundem G; Hultcrantz M; Leongamornlert D; Angelopoulos N; Agnelli L; Auclair D; Zhang Y; Dogan A; Bolli N; Papaemmanuil E; Anderson KC; Moreau P; Avet-Loiseau H; Munshi NC; Keats JJ; Campbell PJ; Morgan GJ; Landgren O; Maura F
Blood Cancer Discov; 2020 Nov; 1(3):258-273. PubMed ID: 33392515
[TBL] [Abstract][Full Text] [Related]
8. Somatic structural variation signatures in pediatric brain tumors.
Yang Y; Yang L
medRxiv; 2023 May; ():. PubMed ID: 37292789
[TBL] [Abstract][Full Text] [Related]
9. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.
Ali SM; Sanford EM; Klempner SJ; Rubinson DA; Wang K; Palma NA; Chmielecki J; Yelensky R; Palmer GA; Morosini D; Lipson D; Catenacci DV; Braiteh F; Erlich R; Stephens PJ; Ross JS; Ou SH; Miller VA
Oncologist; 2015 May; 20(5):499-507. PubMed ID: 25882375
[TBL] [Abstract][Full Text] [Related]
10. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
[TBL] [Abstract][Full Text] [Related]
11. Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases.
Greer SU; Nadauld LD; Lau BT; Chen J; Wood-Bouwens C; Ford JM; Kuo CJ; Ji HP
Genome Med; 2017 Jun; 9(1):57. PubMed ID: 28629429
[TBL] [Abstract][Full Text] [Related]
12. The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration.
Ooki A; Yamaguchi K
Gastric Cancer; 2021 Nov; 24(6):1169-1183. PubMed ID: 34398359
[TBL] [Abstract][Full Text] [Related]
13. A mutational signature in gastric cancer suggests therapeutic strategies.
Alexandrov LB; Nik-Zainal S; Siu HC; Leung SY; Stratton MR
Nat Commun; 2015 Oct; 6():8683. PubMed ID: 26511885
[TBL] [Abstract][Full Text] [Related]
14. Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway.
Lee J; Ou SH
Discov Med; 2013 Aug; 16(86):7-14. PubMed ID: 23911227
[TBL] [Abstract][Full Text] [Related]
15. FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma.
Wang Y; Shi T; Wang X; Hu J; Yu L; Liu Q; Wu N; Liu B; Wei J
J Transl Med; 2021 Sep; 19(1):401. PubMed ID: 34551773
[TBL] [Abstract][Full Text] [Related]
16. Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns.
Sørensen SG; Shrikhande A; Poulsgaard GA; Christensen MH; Bertl J; Laursen BE; Hoffmann ER; Pedersen JS
Elife; 2023 Mar; 12():. PubMed ID: 36883553
[TBL] [Abstract][Full Text] [Related]
17. Structural Variation in Cancer: Role, Prevalence, and Mechanisms.
Cosenza MR; Rodriguez-Martin B; Korbel JO
Annu Rev Genomics Hum Genet; 2022 Aug; 23():123-152. PubMed ID: 35655332
[TBL] [Abstract][Full Text] [Related]
18. Unravelling the tumour genome: The evolutionary and clinical impacts of structural variants in tumourigenesis.
Hamdan A; Ewing A
J Pathol; 2022 Jul; 257(4):479-493. PubMed ID: 35355264
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.
Kawazu M; Kojima S; Ueno T; Totoki Y; Nakamura H; Kunita A; Qu W; Yoshimura J; Soda M; Yasuda T; Hama N; Saito-Adachi M; Sato K; Kohsaka S; Sai E; Ikemura M; Yamamoto S; Ogawa T; Fukayama M; Tada K; Seto Y; Morishita S; Hazama S; Shibata T; Yamashita Y; Mano H
PLoS Genet; 2017 Jun; 13(6):e1006853. PubMed ID: 28636652
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide interrogation of structural variation reveals novel African-specific prostate cancer oncogenic drivers.
Gong T; Jaratlerdsiri W; Jiang J; Willet C; Chew T; Patrick SM; Lyons RJ; Haynes AM; Pasqualim G; Brum IS; Stricker PD; Mutambirwa SBA; Sadsad R; Papenfuss AT; Bornman RMS; Chan EKF; Hayes VM
Genome Med; 2022 Aug; 14(1):100. PubMed ID: 36045381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
